Analyst consensus rating
Arbutus Biopharma Analyst Rating: none
Direct answer
Arbutus Biopharma's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.43.
Forecast evidence checked October 27, 2026.
Get free Arbutus Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.29
- Average price target
- $5.43
- High price target
- $5.43
- Low price target
- $5.43
- Low target gap
- +26.6%
- Target upside
- +26.6%
- High target gap
- +26.6%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Arbutus Biopharma?
Arbutus Biopharma has a verified none consensus. The same dataset has an average price target of $5.43.
How far are Arbutus Biopharma's low and high targets from the recorded price?
The low target implies +26.6%, while the high target implies +26.6%.
How many analysts are included in Arbutus Biopharma's consensus?
The verified consensus includes 1 analysts.
How is Arbutus Biopharma's target upside or downside calculated?
The average target of $5.43 is divided by the recorded price of $4.29, then one is subtracted to produce +26.6%. This does not guarantee a future return.
When was Arbutus Biopharma's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.